Healthcare news summaries — Page 4
Essential facts and source links for recent healthcare stories.
-
IHH subsidiary appeals Tokyo ruling in Fortis-related damages claim against Daiichi
IHH Healthcare says its subsidiary Northern TK Venture has appealed a Tokyo court’s September 10 dismissal of a claim seeking up to 109.3 billion rupees ($1.14 billion) in damages from Daiichi Sankyo over NTK’s purchase of a stake in India’s Fortis Healthcare. -
PicPay targets insurance platform with Kovr deal and 53% Estrutural stake
PicPay’s Kovr acquisition and 53% controlling stake in Estrutural Corretora support its push for an end-to-end insurance platform. The plan pairs Kovr’s digital insurance and underwriting with Estrutural’s brokerage, aiming to give PicPay more control. -
An ER doctor's advice: use AI to understand results, not diagnose
An ER physician says AI chatbots can explain medical reports and help patients prepare for appointments, but should not replace a clinician for diagnosis or treatment decisions. In an Oxford study, people using AI identified relevant conditions in fewer than 35% of cases. -
Blue Cross study links AI use to $942 million in added care costs over two years
A Blue Cross Blue Shield Association study attributes $942 million in added insurer costs to more intensive care over 2024–25, compared with 2023; more frequent billing for secondary diagnoses accounted for $653 million, as providers used AI to identify them. -
Hims & Hers reports 38% revenue growth alongside $86 million GAAP loss
Hims & Hers revenue rose 38% year over year to $753 million. U.S. revenue rose 16% year over year, while Eucalyptus, acquired in June, contributed about $40 million in quarterly sales. The company reported an $86 million GAAP loss and $36 million in negative cash flow. -
Needham initiates GE HealthCare coverage with Buy rating, $93 target
GE HealthCare closed at $64.81 on September 21, 28% below its 52-week high. On September 22, Needham began coverage with a Buy rating and a $93 target, about 44% above the close, saying market skepticism had made the shares attractively valued. -
Establishment Labs raises 2026 revenue guidance after 31.7% quarterly growth
Establishment Labs’ second-quarter revenue rose 31.7% year over year to $67.5 million, while adjusted EBITDA turned positive at $3.7 million from an $8.5 million loss. It raised 2026 revenue guidance to $269 million-$271 million despite an $11.7 million net loss. -
Perdoceo agrees to buy South University, adding 11 campuses
Perdoceo Education agreed to acquire South University, adding 11 campuses and online programs in nursing, pharmacy and physician assistant studies. The deal still needs regulatory and accreditor approvals and could close as early as April 2027. -
Iambic's IPO filing coincides with AbbVie's multi-year AI drug pact
Iambic Therapeutics filed for a U.S. IPO on Sept. 21 and announced a multi-year research pact with AbbVie that day. Its AI platform will design small-molecule programs in immunology, neuroscience and oncology; NVIDIA and Qatar Investment Authority have backed the startup. -
Early retirement requires a health insurance plan before Medicare
Anyone planning to retire before 65 needs to price health coverage before leaving work: Medicare generally starts at 65, and without a spouse’s workplace plan, they may need to buy insurance themselves. Premiums may be much higher than expected and strain a retirement budget. -
Motley Fool puts potential value of Lilly’s retatrutide above $10 billion
The Motley Fool estimates Eli Lilly’s unapproved retatrutide could be worth more than $10 billion to the company, citing Phase 3 weight-loss results and potential use in severe obesity; Lilly plans to submit an approval application in the first quarter of 2027.
